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Background: Good-quality great saphenous vein (GSV) is the preferred conduit for infrainguinal surgical revasculariza-
tions, but it is not available in all patients. We sought to identify the alternative conduit that would maximize cost-
effectiveness in the context of infrapopliteal bypass for critical limb ischemia and nonhealing foot wounds.
Methods: A Markov model was used to create a detailed simulation of 10-year outcomes in a hypothetical Edifoligide for
the Prevention of Infrainguinal Vein Graft Failure (PREVENT) III-type patient cohort undergoing infrainguinal bypass
for nonhealing foot wounds. The following management options were evaluated: (1) conservative therapy (local wound
care, amputation as needed); (2) primary amputation; (3) bypass with autologous alternative vein (AAV), including arm
or lesser saphenous vein; (4) bypass with GSV <3 mm in diameter; (5) bypass with polytetraﬂuoroethylene (PTFE);
(6) cryopreserved venous allograft; and (7) cryopreserved arterial allograft. Estimates of 10-year total costs were incor-
porated into the model. Cost-effectiveness was measured in terms of incremental United States dollars per additional year
of ambulation.
Results: Bypass with AAV had the highest effectiveness as measured in median years of ambulation. After primary
amputation, bypass with PTFE had the lowest total costs. With incremental cost-effectiveness ratios of $5325 and
$21,228, bypass with PTFE or AAV appeared to be cost-effective alternatives to conservative therapy for nonhealing
ischemic wounds. Primary amputation, GSV <3 mm, and allograft options were dominated (ie, more costly and less
effective). Primary amputation was weakly dominated.
Conclusions: Bypass with PTFE or AAV appears to be a cost-effective option for the management of critical limb ischemia
and nonhealing foot wounds when good-quality GSV is not available. (J Vasc Surg 2013;57:1466-70.)Good-caliber single-segment great saphenous vein
(GSV) stands as the best conduit for infrainguinal bypass
graftingdregardless of bypass indication or level of distal
target1dbut is absent in w15% to 20% of patients.2-4 In
the absence of adequate GSV, vascular surgeons perform-
ing surgical revascularizations for nonhealing wounds use
other conduits, including arm veins,3,4 lesser saphenous
veins,5 prosthetic grafts (including Dacron [DuPont, Wil-
mington, Del] and polytetraﬂuoroethylene [PTFE], with
or without distal vein patches or cuffs),6,7 and cryopre-
served venous8 and arterial9 allografts. Each of these
conduit options has some distinct advantages and disadvan-
tages in the setting of infrainguinal revascularizations. A
wealth of literature exists to describe the patency rates
and limb preservations rates associated with the variousthe Division of Vascular Surgery and Endovascular Therapy,
ichael E. Debakey Department of Surgery, Baylor College of Medi-
ne/Michael E. DeBakey Veterans Affairs Medical Center, Houstona;
d the Division of Vascular and Endovascular Surgery Department of
rgery, Brigham and Women’s Hospital, Boston.b
or conﬂict of interest: none.
rint requests: Neal R. Barshes, MD, MPH, Assistant Professor of
rgery, Division of Vascular and Endovascular Surgery, Michael E.
eBakey Department of Surgery, Baylor College of Medicine/Michael
DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd
CL 112), Houston, TX 77030 (e-mail: nbarshes@bcm.tmc.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
lished by Elsevier Inc. on behalf of the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2012.11.115
6alternative conduit options, but none has emerged as an
evidence-based alternative to adequate caliber, single-
segment GSV.
Some doubts have been raised about the total costs and
the cost-effectiveness of limb preservation efforts, even from
those within the ﬁeld of vascular surgery.10-12 Our group
published results of an analysis suggesting that surgical
bypass can achieve high rates of limb preservation within
acceptable levels of cost-effectiveness,13 but the relatively
longer operations, lower patency rates, and higher reinter-
vention rates among patients who lack adequate GSV
conduit raise further doubts about the merits of limb preser-
vation efforts in this subgroup. It is not clear that intervening
on patients lacking endovascular options for revasculariza-
tion and also an adequate-caliber, single-segment GSV
would be more cost-effective than primary amputation or
even expectant management (local wound care alone).
Our goal in this study was to compare the cost-
effectiveness ratios of several conduit options that serve as
alternatives to adequate-caliber single-segment GSV. In
particular, we sought to determine whether limb preserva-
tion efforts were within acceptable limits and if one partic-
ular conduit option appeared to be most cost-effective.
METHODS
Conduit options evaluated and overall study
design. The focus of this study was to compare manage-
ment options for patients with nonhealing foot wounds
and chronic limb ischemia who had reconstructible infrain-
guinal arterial occlusive disease but lacked adequate caliber
(ie, $3 mm) single-segment GSV and for whom an
Table I. Median values for total (direct and indirect)
costs of hospitalizations for various index procedures
done for critical limb ischemia with nonhealing foot
wounds in United States dollars (USD)a
Procedure
Median cost
of associated
hospitalization (USD) SE (USD)
Endovascular intervention
(initial)
26,509 2153
Bypass operation 44,635 6508
Major amputation 34,251 8305
Revision of surgical bypass 28,039 5075
Endovascular reintervention 13,138 2515
SE, Standard error.
aFrom Barshes et al.13
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therefore examined the following management options:
1. Conservative management with local wound care
and primary amputation as needed;
2. Primary major amputation;
3. Infrainguinal bypass using autologous alternative vein
(AAV), comprising upper or lower extremity vein (but
not single-segment GSV) that was single-segment or
multiple-segments (ie, composite or spliced);
4. Infrainguinal bypass using GSV <3 mm in diameter;
5. Infrainguinal bypass using PTFE, with or without
a vein patch;
6. Infrainguinal bypass using cryopreserved venous allo-
graft; and
7. Infrainguinal bypass using cryopreserved arterial
allograft.
We used the general framework of the Model to Opti-
mize Value in Ischemic Extremities (MOVIE) study
for the current work.13 In brief, the MOVIE study was
a cost-effectiveness analysis of contemporary strategies of
managing chronic limb ischemia associated with nonhealing
foot wounds in ambulatory, independently living patients.
The patient demographics and baseline characteristics
were modeled on an Edifoligide for the Prevention of
Infrainguinal Vein Graft Failure (PREVENT) III-type
cohort, which comprised a study population that was 64%
diabetic, 64% male, 28% nonwhite, and was a median age
of 69 years.13
Clinical parameter estimates and utility estimates were
obtained from a thorough review of pre-existing literature
and included a baseline annual mortality rate ofw11.4%.14
The clinical parameter estimates speciﬁc to various conduit
options were obtained from the best-quality literature avail-
able, preferentially from clinical trials, meta-analyses of
observational studies, or from other observational studies.
Most of the studies on which the outcome parameters
were based were predominately studies of bypasses to
infrapopliteal distal targets but did include some femoro-
popliteal bypasses.15-17 Estimates of the costs associated
with revascularization and major amputation were obtained
using a transition cost accounting system to obtain patient-
level activity-based estimates of the direct and indirect costs
(Table I, online addendum).13 The costs associated with
other clinical states (eg, nonhealed wounds receiving
local wound care) were obtained from a literature review.
The goal was to include total costs (not charges) from the
societal perspective whenever such cost estimates existed.18
A computer-simulated, probabilistic Markov model was
used to compare the cost-effectiveness associated with
various conduit choices. The simulations consisted of
1000 trials, each composed of cohorts of 1000 hypothetical
patients simulated during a 10-year time horizon. All
modeling and analysis was performed using Excel 2010 soft-
ware with Visual Basic for Application (Microsoft Corp,
Redmond, Wash). All cost-values are reported in 2011
United States dollars (USD) and represent a median valueunless otherwise noted. The standard discounting rate of
3.5% was applied to utility and cost values.19
The primary end point was the incremental cost-
effectiveness ratio (ICER) expressed as cost per year of
preserving ambulatory ability in any form, including
through successful limb salvage and preservation of ambula-
tory ability or through major amputation with ambulation
using a limb prosthesis. All ICER ratios are presented as
the comparison of one intervention vs the next lowest cost
alternative.20 These comparisons are described using terms
that are standard for cost-effectiveness analyses, including
“strongly dominated” (for an option that is both less effec-
tive and more costly than another alternative) and “weakly
dominated” (for an option that is less effective and less
costly than another alternative but has a higher ICER).18
Secondary end points included cost per year of limb preser-
vation, rate of limb preservation, and total costs.
Deterministic sensitivity analyses. Parameters with
higher degrees of uncertainty about the estimates were
subjected to deterministic sensitivity analyses. Two main
parameters were the focus of these analyses: the cost of
bypass using AAV and the cost of bypass using cryopre-
served arterial allograft. The base-case scenario assumed
that any additional costs associated with increased operative
time or increased postoperative costs (prolonged index
hospitalization, higher readmission rate, additional costs
associated with complications of vein harvesting), or both,
in the performance of a bypass using AAV was offset by the
conduit not having any additional procurement costs. In
addition, we assumed the additional direct costs associated
with procurement of cryopreserved venous allograft and
PTFE prosthetic graft was offset by the shorter operative
time. A one-time additional initial direct cost of $5000 was
used in the base-case scenario for cryopreserved arterial
allograft; this was varied over the range of $0 to $5000 in
the deterministic sensitivity analyses.
RESULTS
Comparison of clinical outcomes and cost-effec-
tiveness. Themedian 5-year limb salvage rates seen over the
1000 consecutive simulations ranged from 60.6% for PTFE
Table II. Clinical outcomes estimated from 1000 consecutive simulations of the Markov model (median data)
Incidence of major
amputation after bypass
Conduit option
Limb salvage
rate at 5,
% (range)
#1 year,
% (range)
2-10 years,
% (range)
Annual incidence
of revisions to
restore or maintain patency,
% (range)
Source for
parameter
estimates
(ﬁrst author)
Good-caliber,
single-segment GSVa
80.7 (75.2-85.3) 10.6 (7.1-14.4) 2.6 (1.4-3.8) 22.7 (19.2-26.4) Conte,20 Berceli21
AAV 78.9 (72.1-83.9) 11.6 (7.5-14.4) 3.1 (1.7-4.6) 49.0 (29.1-65.6) Albers,22 Armstrong23
PTFE 6 vein patch 60.6 (47.1-73.2) 22.3 (13.4-32.8) 6.2 (3.4-9.1) 24.8 (13.7-36.2) Albers,16 Neville6
Small-caliber GSV 77.1 (56.5-88.2) 14.1 (4.5-27.2) 2.6 (1.4-3.8) 40.6 (15.5-65.5) Schanzer,2 Slim17
Cryopreserved allograft
Venous 62.4 (42.1-78.2) 22.0 (13.4-32.8) 4.8 (2.7-7.1) 52.6 (29.0-76.9) Albers17
Arterial 79.6 (70.1-86.4) 19.0 (6.5-35.3) 3.4 (1.9-5.0) 52.6 (29.0-76.9) Albers17
AAV, Autologous alternative vein; GSV, great saphenous vein; PTFE, polytetraﬂuoroethylene.
aPresented here for comparison purposes only; good-caliber single-segment saphenous vein was not included in the analysis.
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median 5-year limb salvage rate for conservative manage-
ment was 26.7% (range, 14.7%-45.5%). The median inci-
dence of major amputation during the ﬁrst year after bypass
ranged from 11.6% for AAV to 22.0% for cryopreserved
venous allograft and to 22.3% for PTFE. During subsequent
years, the incidence rates of major amputation were much
more similar, ranging from 2.6% to 6.2%. Themedian 5-year
patient survival rates for all management options were
similar, ranging from 50.5% to 52.0% (minimum of 39.5%
and maximum of 63.5% over the 1000 simulations).
The median 10-year total costs associated with each
management option are presented in Table III. Conserva-
tive management had the lowest median 10-year cost, at
$73,948. The costs of bypass with PTFE were only slightly
higher than the costs of primary amputation ($87,463 vs
$84,906, respectively). The median 10-year costs of bypass
with AAV, cryopreserved venous allograft, and small-
caliber GSV were also similar, ranging from $93,814 to
$95,741. The median 10-year cost of bypass with cryopre-
served arterial allograft was $100,575, the highest among
all the options evaluated. Conservative management
produced a median of 1.9 years of ambulation, the lowest
health beneﬁt among the options evaluated (Table III).
Primary amputation resulted in a median of 2.9 years of
ambulation, whereas bypass with various conduits resulted
in 4.3 to 4.5 years of ambulation.
Compared with conservative management, bypass with
PTFE had an ICER of $5325 per year of ambulation and
was therefore the ﬁrst cost-effective alternative to conserva-
tive therapy (Table III; Fig). Bypass with AAV had an
ICER of $21,228 per additional year of ambulation vs
bypass with PTFE ($7508 per year of ambulation over
conservative therapy) and therefore also appeared to be
a cost-effective alternative. Primary amputation was weakly
dominated by bypass with PTFE (lower cost and lower
effectiveness but higher ICER). Bypass with small-caliber
GSV, bypass with cryopreserved venous allograft, and
bypass with cryopreserved arterial allografts were stronglydominated by bypass with AAV (higher cost and lower
effectiveness).
Results of deterministic sensitivity analyses. The
base-case scenario assumed an additional $5000 of
direct costs associated with the procurement of cryo-
preserved arterial allograft that was not offset by the
decrease in operative time. To test whether the results or
conclusions of the analysis changed based on this esti-
mate, we performed a deterministic sensitivity analysis
assuming no additional direct costs associated with this
conduit. In this sensitivity analysis, the median total costs
decreased to $94,708 (range, $69,034-$132,699), but
this option remained dominated (ie, more costly but less
effective) compared with bypass with PTFE and bypass
with AAV.
In another deterministic sensitivity analysis, we
included up to an additional $10,000 of additional costs
associated with AAV. The median total costs for bypass
with AAV increased up to $103,557 (range, $77,470-
$162,614) in these analyses. In these sensitivity analyses,
the ICER of bypass with AAV and bypass with small-
caliber GSV became equivalent when the additional total
costs associated with bypass with AAV exceeded w$3000.
DISCUSSION
Single-segment GSV remains the preferred conduit for
infrainguinal bypass but may be unavailable in 15% to 20%
of patients in need of a bypass. This has led many groups to
describe their experience with various alternative conduits.
Using purely clinical end points, none has emerged as
a clear second-best alternative. In this context and with
increasing emphasis on costs and cost-effectiveness in
health care, the current study was undertaken to evaluate
alternative conduits from the perspective of cost-
effectiveness.
Three main conclusions can be drawn from the current
results. First, infrainguinal bypass with PTFE or AAV may
be a reasonably cost-effective alternative to conservative
management (local wound care and major amputation as
Table III. The costs, health beneﬁts, and cost-effectiveness of various conduit options used for infrapopliteal bypass in
the absence of adequate caliber, single-segment great saphenous vein (GSV)
Management option
Cost in 2011 USD,
median (range)
No. of ambulatory years,
median (range)
Incremental cost per
limb-year in 2011 USD
Conservative management 73,948 (45,118-111,554) 1.912 (1.182-2.477) .
Primary amputation 84,906 (42,540-139,226) 2.931 (2.142-3.757) Weakly dominated
Bypass with
PTFE 6 vein patch 87,463 (62,533-119-658) 4.256 (3.414-5.236) $5325
AAV 93,814 (68,061-126,033) 4.558 (3.673-5.400) $21,228
Cryopreserved venous allograft 95,557 (68,604-128,076) 4.242 (3.414-5.236) Dominated
Small-caliber GSV 95,741 (68,590-124-632) 4.537 (3.686-5.585) Dominated
Cryopreserved arterial allograft 100,575 (73,092-131,244) 4.352 (3.490-5.329) Dominated
AAV, Autologous alternative vein; PTFE, polytetraﬂuoroethylene; USD, United States dollars.
Fig. Cost-effectiveness acceptability curves demonstrate the probability of the conduit options evaluated (vertical axis)
having an incremental cost-effectiveness ratio (2009 United States dollars [USD] per quality-adjusted life-year) at or
below various ceiling ratios (horizontal axis). PTFE, Polytetraﬂuoroethylene.
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chronic limb ischemia. Bypass with PTFE appears to have
a lower total cost and good outcomes. Bypass with AAV
appears to have better outcomes but at a higher total
cost, although both options have ICERs that appear
reasonable when compared with conservative management
($5305 and $7508, respectively, per additional year of
ambulation over conservative management). Bypass with
small-caliber GSV may also be a reasonable alternative if
the additional costs associated with AAV exceed $3000
and the clinical outcomes of small-caliber GSV are similar
to those reported in the few publications that exist on
this topic.2,21
Some qualiﬁcations of these conclusions must be
made. The results of this study are based on estimates of
clinical outcome and health utility parameters derived
from the literature and cost parameters drawn from
a single-center study of costs.13 We do believe that theseparameters are representative of most U.S. nonfederal
medical centers. As with clinical studies (including random-
ized trials), however, the generalizability of these ﬁndings
to any particular practice setting depends on speciﬁc
parametersdincluding baseline patient characteristics, clin-
ical outcomes, and health care system cost structured
being at least comparable to the parameter estimates used
in this study. Additional estimates of the long-term costs
associated with bypass with various alternative conduits
(especially small-caliber GSV, for which very few studies
exist) are necessary and would help inform more precise
ICER estimates.
The second key conclusion is that venous and arterial
cryopreserved allografts do not appear to be good alterna-
tives to conservative management compared with conserva-
tive management or bypass with PTFE or AAV. The option
of bypass with either of these conduits was dominated in this
cost-effectiveness analysis, meaning they were associated
JOURNAL OF VASCULAR SURGERY
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appears not to be due to increased costs associated with the
graft material itself but rather a combination of higher rein-
tervention rates and lower limb preservation rates. Indeed,
venous and arterial allografts both remain dominated even
when the costs of the grafts are assumed to be zero.
Finally, we found that primary amputation does not
appear to be a cost-effective alternative to conservative
management or bypass. Primary amputation was weakly
dominated by bypass with PTFE, meaning that the ICER
of primary amputation vs conservative management was
higher than the ICER of bypass with PTFE (the next-
cheapest alternative) vs primary amputation. Primary
amputation remains a standard approach for patients with
a nonsalvageable limb, patients who are nonambulatory
at baseline, and for patients who are not interested in
limb preservation efforts. The results of this analysis,
however, suggest that primary amputation does not appear
to be justiﬁed on the basis of cost-effectiveness in patients
who otherwise appear to be candidates for limb preserva-
tion efforts, as some authors have suggested.11,12
We have previously reported the ICERs associated with
managing nonhealing wounds in the ischemic lower limb
in the form of costs per quality-adjusted life-year, and the
ICER of infrainguinal bypass seems well within the ceiling
values suggested for reimbursement in the United States.13
The recent Patient Protection and Affordable Care Act,
however, has discouraged the use of measures such as
quality-adjusted life-years that “[discount] the value of
a life because of an individual’s disability,”22 and this
does pose some limitations for formal cost-utility anal-
yses.23 In this study we therefore instead focused on cost
per year of ambulatory ability because it is the preservation
of ambulatory abilitydnot simply the avoidance of major
amputation or “anatomic” limb salvagedthat is ultimately
the goal of revascularization in the context of non-healing
wounds on ischemic limbs.
CONCLUSIONS
Future studies in the ﬁeld of limb preservation should
continue to focus on functional, patient-centered outcomes
and consider costs whenever possible. We hold that evalua-
tion of cost per year of ambulation serves as a useful measure
for future evaluations of the value of limb preservation
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